Register

Rheumatology

Lupus nephritis   

Questions discussed in this category

Do you choose rituximab or calcineurin inhibitors for patients with class IV/V lupus nephritis who are refractory to standard of care therapies?
1 Answer available
Would you feel comfortable adding benlysta to patient already taking both mycophenolate and tacrolimus (and hydroxychloroquine) who still has some evidence of active lupus nephritis?
3 Answers available
Would you treat a patient aggressively for lupus nephritis if they have persistent proteinuria over 1 gram but cannot get a timely kidney biopsy?
3 Answers available
Is there a role for voclosporin in non-renal lupus?
1 Answer available
Is there a role for eculizumab in the management of refractory lupus nephritis?
3 Answers available
Do you routinely advise patients waiting for a kidney transplant to seek referrals at multiple institutions to decrease waiting time?
1 Answer available
Is there a role for measuring serum mycophenolate mofetil levels (or its active metabolite) in the management of lupus nephritis?
1 Answer available
Do you routinely monitor the QTc when adding voclosporin to hydroxychloroquine in a patient with lupus nephritis?
1 Answer available
What do you use for treatment induction in pure class V lupus nephritis with nephrotic-range proteinuria when MMF is contraindicated?
2 Answers available
In which clinical scenarios is relying on the urine protein-to-creatinine ratio as a measure of proteinuria unreliable, and interpretations should be made looking at urine protein and urine creatinine separately?
1 Answer available
How do you approach recurrent costochondritis in an SLE patient with nephritis who is otherwise controlled on MMF and HCQ but can't take NSAIDs?
2 Answers available
How would you approach the treatment of a patient who, during a hospitalization, was initially diagnosed with TTP and treated with PLEX with good response, but renal biopsy then resulted class IV LN along with changes of thrombotic microangiopathy?
4 Answers available
How would you treat a patient with active lupus nephritis (class 3/4) who requires PD-1 immunotherapy for refractory metastatic renal cell carcinoma?
2 Answers available
In patients with lupus nephritis on maintenance therapy, is there additional benefit in utilizing 2 grams vs 3 grams of mycophenolate mofetil (MMF) daily?
3 Answers available
What is your approach to using NIH activity and chronicity indices from renal biopsy in tailoring immunosuppression to a patient with new lupus nephritis?
3 Answers available
Would you consider adding voclosporin to belimumab and MMF in the setting of active proteinuria, rather than switching agents?
3 Answers available
How do you approach the management of immunosuppression in patients with lupus nephritis that go on to dialysis?
3 Answers available
Do you think there is a role for belimumab in treating lupus nephritis and if so, in which patients would you considering adding it on?
Did the recently published BLISS-LN trial change your practice?
2 Answers available
What is your approach to bladder cancer surveillance in patients who have received cyclophosphamide?
1 Answer available
How do steroids and/or DMARDs affect biopsy results if a renal biopsy for suspected lupus nephritis is delayed?
1 Answer available
In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?
1 Answer available


Papers discussed in this category

Arthritis and rheumatism, 2012-04
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.
Ann Rheum Dis, 2013 Jun 05
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids.
Arthritis and rheumatism, 2010-01
Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.
J. Rheumatol., 2019 Sep 01
Malignancies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: A Population-based Cohort Study.
N Engl J Med,
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Kidney international, 2009-12
A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis.
Clinical journal of the American Society of Nephrology : CJASN, 2010-07
Comparison of urinary albumin-creatinine ratio and albumin excretion rate in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study.
Journal of the American Society of Nephrology : JASN, 2010-08
Comparison of different measures of urinary protein excretion for prediction of renal events.
Am J Kidney Dis, 2016 Sep 16
Timed Urine Collections for Albumin and Protein: "The King Is Dead, Long Live the King!".
J Rheumatol, 2004 Aug
Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis.
Kidney international, 2019-01
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Lancet, 2021 May 07
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
The American journal of medicine, 1983-09
Prognostic factors in lupus nephritis. Contribution of renal histologic data.
Arthritis care & research, 2011-06
Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.
Kidney international, 2018-04
Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices.
Kidney Int, 2010 Feb 24
Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system.
Journal of clinical pharmacology, 2011-08
Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients.
Arthritis Rheumatol, 2021 May 02
Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus.
Arthritis Rheum,
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus.
Lupus,
Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis.
Arthritis Rheumatol, 2020 Jan 07
Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy.
Transplant Proc,
A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
Transpl Int, 2014 Aug 22
Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?
J Clin Med, 2021 Feb 09
Management of Lupus Nephritis.
Lancet Oncol, 2019 Jan
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities.
The New England journal of medicine, 2019-01-24
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
N Engl J Med, 2022 Dec 22
Recombinant ADAMTS13 for Hereditary Thrombotic Thrombocytopenic Purpura.
Rheumatology international, 2017 Mar 03
Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence.
Rheumatology (Oxford, England), 2015 Aug 27
Eculizumab as rescue therapy in severe resistant lupus nephritis.
Arthritis and rheumatism, 2011-12
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Arthritis Rheumatol, 2017 Apr 07
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Lancet (London, England), 2011 Feb 04
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Arthritis & rheumatology (Hoboken, N.J.), 2023 Jul 19
Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.
Lupus Sci Med, 2018
Serum albumin at 1 year predicts long-term renal outcome in lupus nephritis.

Related Topics in Rheumatology

Copyright © 2024 theMednet
All Rights Reserved.